Ads
related to: treatments for osteoporosis in women- Bone-Building Diet Guide
Read About The Best Foods For Bone
And AlgaeCal's Secret Weapon
- FAQs
Read Through the FAQs.
Get Your Queries Answered.
- Shop All Products
Check the Available Fish Oil And
Blood Test Kit. View Pricing.
- Our Secret Formula
Learn more about our Bone Builder.
AlgaeCal Formula Works
- Who is AlgaeCal
Guided By Science Powered By Nature
Global Leaders in Bone Health
- AlgaeCal Success Stories
Refer To the Success Stories
And Get Valuable Insights.
- Bone-Building Diet Guide
Search results
Results From The WOW.Com Content Network
Bone loss increases after menopause in women due to lower levels of estrogen, and after andropause in older men due to lower levels of testosterone. [10] Osteoporosis may also occur due to a number of diseases or treatments, including alcoholism, anorexia, hyperthyroidism, kidney disease, and after oophorectomy (surgical
Osteoporosis in the vertebrae can cause serious problems for women. A fracture in this area can happen during day-to-day activities like climbing stairs, lifting objects, or bending forward when ...
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. [6] For osteoporosis it is less preferred than bisphosphonates. [6] It is also used to reduce the risk of breast cancer in those at high risk. [6] It is taken by mouth. [6]
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; [13] for the increase of bone mass in men with primary or hypogonadal osteoporosis; [13] and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
In November 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Obodence, intended for the treatment of osteoporosis in women who have been through menopause, treatment of bone loss linked to hormone ablation in men at increased risk of fractures, or treatment of bone loss ...
Ads
related to: treatments for osteoporosis in women